Ron Gooden: The Journey of Resilience, Living with MCI
- Ron Gooden: The Journey of Resilience, Living with MCI Mark Turnbull: Certified Senior Advisor (CSA) and Radio Host 1:01:12
“It’s all about challenging your brain.” – Ron Gooden
Ron Gooden shares his personal journey with a form of Alzheimer’s disease, Mild Cognitive Impairment (MCI) to discuss the early signs he noticed, the challenges he faced in getting a proper diagnosis, and the coping strategies he has employed since his diagnosis.
A major source of strength that Ron stresses is the importance of family support and the proactive steps he has taken to manage his condition with his wife of over 50 years by their side.
Join Host, Mark Turnbull on this insightful conversation of the power and strength to live in the moment to aid in living a fulfilling and satisfying life.
Special Thanks to Sponsor: Royal Hospice Oregon
#Aging #Alzheimers #MCI #AgingToday
LEQEMBI® (lecanemab-irmb, 100 mg/mL, injection for intravenous use), made by Eisai Inc. in partnership with Biogen, was approved by the FDA in July 2023 under the traditional approval pathway for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia (collectively known as early AD). LEQEMBI is the first FDA approved anti-amyloid treatment for AD shown to slow disease progression and cognitive and functional decline in adults with early AD. Even though it is not possible to stop AD from getting worse, with LEQEMBI, one can take steps to slow how fast it progresses. The treatment was tested in a large 18-month clinical study in patients with MCI and mild dementia due to early AD. LEQEMBI can cause serious side effects including amyloid related abnormalities (ARIA), serious allergic reactions and infusion-related reactions. Some people may have small spots of bleeding in or on the surface of the brain, sometimes fatal events with larger areas of bleeding have occurred. Patients who may be eligible for treatment with LEQEMBI should ask their doctor about testing for a genetic risk factor that may cause an increased risk for ARIA. It is important they also tell their doctor about all the medicines they take, including medications to reduce blood clots from forming such as antithrombotic medicines like aspirin. Some medicines can increase the risk for larger areas of bleeding in the brain. Most common side effects included infusion related reactions, swelling in areas of the brain, and headaches. These are not all the possible side effects of LEQEMBI. Please see full Prescribing Information for LEQEMBI, including Boxed WARNING.
